Mikael Mahler Selected Research

Neoplasms (Cancer)

4/2005	Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.
3/2004	Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mikael Mahler Research Topics

Disease

2	Neoplasms (Cancer) 04/2005 - 03/2004
1	Lewis Lung Carcinoma 04/2005
1	Carcinoma (Carcinomatosis) 03/2004

Drug/Important Bio-Agent (IBA)

2	carbazoleIBA 04/2005 - 03/2004
1	Irinotecan (Camptosar)FDA LinkGeneric 04/2005
1	Pharmaceutical PreparationsIBA 04/2005
1	BMS 250749IBA 04/2005
1	3,9- difluoro- 12,13- dihydro- 13- (6- aminoglucopyranosyl)- 5H,13H- benzo(b)thienyl(2,3- a)pyrrolo(3,4- c)carbazole- 5,7(6H)- dioneIBA 03/2004